| Package | us.nlm.vsac |
| Type | ValueSet |
| Id | 2.16.840.1.113883.3.1444.5.238 |
| FHIR Version | R4 |
| Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.1444.5.238/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.238 |
| Version | 20220112 |
| Status | active |
| Date | 2022-01-12T01:02:12-05:00 |
| Name | FirstLineDrugTherapyForMetastaticColorectalCancer |
| Title | First Line Drug Therapy for Metastatic Colorectal Cancer |
| Realm | us |
| Authority | hl7 |
| Purpose | (Clinical Focus: The purpose of this value set is to represent concepts of medications for first-line drug therapy for metastatic colorectal cancer.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication for first-line drug therapy for metastatic colorectal cancer: leucovorin, panitumumab, bevacizumab, capecitabine, cetuximab, pembrolizumab, fluorouracil, oxaliplatin, irinotecan, ipilimumab, nivolumab.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.) |
No resources found
| CodeSystem | |
| rxnorm | RxNorm |
| rxnorm | RxNorm |
| ValueSet | |
| 2.16.840.1.113762.1.4.1116.169 | Irinotecan Injectable |
| 2.16.840.1.113762.1.4.1116.179 | Bevacizumab Injectable |
| 2.16.840.1.113762.1.4.1116.210 | Capecitabine Oral |
| 2.16.840.1.113762.1.4.1116.61 | Cetuximab Injectable |
| 2.16.840.1.113762.1.4.1116.63 | Panitumumab Injectable |
| 2.16.840.1.113883.3.1444.3.100 | Injectable Fluorouracil |
| 2.16.840.1.113883.3.1444.3.132 | Oxaliplatin Injectable |
| 2.16.840.1.113883.3.1444.3.187 | Ipilimumab Injectable |
| 2.16.840.1.113883.3.1444.3.188 | Nivolumab Injectable |
| 2.16.840.1.113883.3.1444.3.189 | Pembrolizumab Injectable |
| 2.16.840.1.113883.3.464.1003.196.11.1205 | Leucovorin |
No narrative content found in resource
FHIR